| Old Articles: <Older 2251-2260 Newer> |
|---|
 |
The Motley Fool
August 1, 2005
Stephen D. Simpson |
Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.   |
Bio-IT World
July 2005
Kevin Davies |
Trial Registries on Trial A group of influential editors from some of the world's boutique medical journals begin enforcing a new policy that would bar drug companies from publishing clinical trial data unless those trials are registered in a suitable public database. |
Bio-IT World
July 2005
Maureen McDonough |
MIT President Speaks Susan Hockfield, president of MIT, stressed the importance of industry and academia collaboration in her keynote address at the Massachusetts Biotechnology Council's annual meeting on May 26. |
Bio-IT World
July 2005
David Fishbach |
Does EDC Herald the End of CTMS? Clinical trial managements systems (CTMSs) and Electronic data capture systems (EDCs) are compared with respect to their history, advantages and disadvantages. Studies suggest both have enough advantages to survive in some form of integrated solution. |
Bio-IT World
July 2005
Michael A. Greeley |
CEO Lessons on Product and Market In the face of extraordinary R&D budgets generated by biopharma industries, bio-IT companies must refine their value propositions in the hopes that meaningful (predictable and repeatable) revenue streams can be created. |
Bio-IT World
July 2005
Scott Lundstrom |
Indicators Point to Spending Gains Life science organizations expect an average 4.6% increase in their IT spending over the next 12 months. It marks the fourth consecutive quarter in which life science organizations expressed expectations for IT spending growth. |
Bio-IT World
July 2005 |
News Blast Applied Allied... Third Phase... Broad Broadens... In the Pipeline... |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Bio-IT World
July 2005
Johan Bostrom |
Affymetrix to Acquire ParAllele The companies have been working together for the past two years, with Affymetrix using ParAllele's assay technology with the Affymetrix GeneChip technology. Affymetrix expects to strengthen its assay R&D capabilities and add knowledge in specific assay capabilities through the acquisition. |
Bio-IT World
July 2005
Mark D. Uehling |
Hal, Open the Refrigerator Door Can a humble refrigerator make your high-throughput screening (HTS) campaigns more productive? Yes, Eli Lilly discovered. The TekCel robots can deliver plates (and data) more quickly than humans, at the rate of several hundred samples per hour, around the clock. |
| <Older 2251-2260 Newer> Return to current articles. |
